1 / 9

Peter Graaff Department of Essential Drugs and Medicines Policy Department of HIV

Access to essential medicines for HIV/AIDS update on WHO activities within UN access framework. Peter Graaff Department of Essential Drugs and Medicines Policy Department of HIV World Health Organization. Selection. 1. Rational selection and use. 2002:

thomas-buckley
Download Presentation

Peter Graaff Department of Essential Drugs and Medicines Policy Department of HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Access to essential medicines for HIV/AIDS update on WHO activities within UN access framework Peter Graaff Department of Essential Drugs and Medicines Policy Department of HIV World Health Organization

  2. Selection 1. Rational selection and use 2002: • WHO guidelines for a public health approach to on scaling up antiretroviral therapy in resource limited settings : http://www.who.int/HIV • standardized and simplified regimens • simplified patient monitoring • 12 ARVs on WHO Model EML & WMF 2003 (planned) • Update and prioritization  ? Global stand. 1st line

  3. Affordable prices 2. Affordable prices for governments, healthcare providers and consumers - strategies: • National policy • exemption from taxes, import duties • price regulation (producer prices, distribution margins) • WTO/TRIPs provisions • Market dynamics • generic competition • Procurement management • price information • patent status and regulatory status • price negotiation • group purchasing (public, NGO - national, regional)

  4. Affordable prices Indicative price information promotestransparency and competition • MSH-WHO essential drugs price indicator • UNICEF, UN-AIDS, WHO Sources and Prices (selected medicines and diagnostics) • Pharmaceutical starting materials • Antiretroviral drugs in the Americas • AFRO Essential Drugs

  5. UN Drug AccessInitiative Generic competition in Brazil 5-company offer Generic company offer Affordable prices Advocacy, corporate responsiveness, & market forces have reduced antiretrovial prices >95% in a few years UNDCP UNDP UNESCO UNFPA WIPO

  6. Financing 3. Sustainable financing In over 38 countries public drug expenditures are <US$2 per capita - inadequate by most estimates Key actions: • Increase public funding for cost-effective drugs • Expand drug benefits in health insurance • Seek external funding for the poorest populations (e.g. Global Fund) NB: This “leg” of the access table needs to be strengthened

  7. Reliable systems Pilot Procurement, Quality and Sourcing Project • Objective: • Establish a Model Quality Assurance System for Procurement of Pharmaceuticals • Pre-qualification of suppliers of HIV/AIDS-related pharmaceutical products • Quality standards of newer HIV medicines • Improved capacity of national regulatory bodies • Partners: • UNAIDS, UNFPA, UNICEF, WHO, World Bank • Products: • 50 ARVs, 44 mono, 5 double and 1 triple combination

  8. New developments …….. 3x5Scale up access to ARV to 3million by 2005 • 300,000 out of 6,000,000 who should be on treatment in the developing world receive ARVs(Africa: 50,000 out of 4,000,000) • 22/09/03 emergency declaration • 01/12/03 World AIDS day. Present implementation plan to include: • Intensified country support (priority countries) • Tools (simplified) to move beyond capital and medical doctor • “AIDS drug and diagnostic facility” • ……..

  9. 4. Summary • UN, WHO and partners are active in all aspects of access to HIV/AIDS medicines • Key tools available to governments and NGOs: • Treatment guidelines and essential medicines list • Price information • Pre-qualified suppliers and products • Patent status and regulatory status • Guidance on use of TRIPS safeguards • Policy and training tools in supply management (pricing, donations, procurement and supply management) • 3x5 should “affect” us all

More Related